

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GOLDEN MEDITECH HOLDINGS LIMITED

金衛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 801)

PROFIT WARNING

This announcement is made by Golden Meditech Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (“**SFO**”) (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the unaudited consolidated management accounts of the Group for the period ended 30 September 2013, the Group is expected to record a loss for the current reporting period, as compared to a profit recorded for the corresponding period in 2012. The Board considers that such substantial increase in loss is mainly attributable to (i) the non-cash loss in a subsidiary as a result of the fair value accounting basis of the convertible notes issued by one of the subsidiaries of the Group, China Cord Blood Corporation (“**CCBC**”). As of 30 September 2013, the share price of CCBC rose to US\$3.80 per share, which was approximately 33.90% above the conversion price of the convertible notes of CCBC, resulting in an increase in the fair value of the convertible notes; and (ii) unrealised loss as a result of the decline in market values of certain security investments held by the Group, as opposed to a gain recorded in the corresponding period last year. The losses as stated above were recognised in compliance with the currently applicable accounting standards of the Group. They are non-cash in nature and have no effect on the Group’s business operations for the current reporting period. The Board considers that, excluding the above mentioned non-cash gains and losses, the results from the Group’s underlying operating businesses for the period ended 30 September 2013 should not show a significant fluctuation from that of the corresponding period in 2012.

As the Company is still in the process of finalising the consolidated interim results for the period ended 30 September 2013, the information contained in this announcement is only a preliminary assessment by the management of the Company based on the unaudited consolidated management accounts of the Group for the period ended 30 September 2013. The finalised interim results of the Group for the period ended 30 September 2013 is expected to be announced on 25 November 2013. Shareholders and potential investors are advised to read the interim result announcement with care when it is published.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
GOLDEN MEDITECH HOLDINGS LIMITED
Kam Yuen
Chairman

Hong Kong, 18 November 2013

As at the date of this announcement, the Board comprises 9 directors. The executive Directors are Mr. KAM Yuen (Chairman), Mr. LU Tian Long, Mr. KONG Kam Yu and Mr. YU Kwok Kuen, Harry; the non-executive Director is Ms. ZHENG Ting and the independent non-executive Directors are Prof. CAO Gang, Mr. FENG Wen, Mr. GAO Zong Ze, and Prof. GU Qiao.